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STUDY PROTOCOL Open Access
REstricted Fluid REsuscitation in Sepsis-
associated Hypotension (REFRESH): study
protocol for a pilot randomised controlled
trial
Stephen P. J. Macdonald1,2,11*, David McD Taylor3,4, Gerben Keijzers5,6,7, Glenn Arendts1,8,11, Daniel M. Fatovich1,2,11,
Frances B. Kinnear9, Simon G. A. Brown1,10,11, Rinaldo Bellomo12,13, Sally Burrows14, John F. Fraser6,15,16,
Edward Litton17, Juan Carlos Ascencio-Lane10, Matthew Anstey18, David McCutcheon1,11,19, Lisa Smart1,11,
Ioana Vlad20, James Winearls7,16,21 and Bradley Wibrow18
Abstract
Background: Guidelines recommend an initial intravenous (IV) fluid bolus of 30 ml/kg isotonic crystalloid for patients
with sepsis and hypotension. However, there is a lack of evidence from clinical trials to support this. Accumulating
observational data suggest harm associated with the injudicious use of fluids in sepsis. There is currently equipoise
regarding liberal or restricted fluid-volume resuscitation as first-line treatment for sepsis-related hypotension. A
randomised trial comparing these two approaches is, therefore, justified.
Methods/design: The REstricted Fluid REsuscitation in Sepsis-associated Hypotension trial (REFRESH) is a multicentre,
open-label, randomised, phase II clinical feasibility trial. Participants will be patients presenting to the emergency
departments of Australian metropolitan hospitals with suspected sepsis and a systolic blood pressure of < 100 mmHg,
persisting after a 1000-ml fluid bolus with isotonic crystalloid. Participants will be randomised to either a second 1000-ml
fluid bolus (standard care) or maintenance rate fluid only, with the early commencement of a vasopressor infusion
to maintain a mean arterial pressure of > 65 mmHg, if required (restricted fluid). All will receive further protocolised
fluid boluses (500 ml or 250 ml, respectively), if required during the 6-h study period. The primary outcome measure is
total volume administered in the first 6 h. Secondary outcomes include fluid volume at 24 h, organ support ‘free days’
to day 28, 90-day mortality, and a range of feasibility and process-of-care measures. Participants will also undergo serial
measurement, over the first 24 h, of biomarkers of inflammation, endothelial cell activation and glycocalyx degradation
for comparison between the groups.
Discussion: This is the first randomised trial examining fluid volume for initial resuscitation in septic shock in an
industrialised country. A pragmatic, open-label design will establish the feasibility of undertaking a large, international,
multicentre trial with sufficient power to assess clinical outcomes. The embedded biomarker study aims to provide
mechanistic plausibility for a larger trial by defining the effects of fluid volume on markers of systemic inflammation
and the vascular endothelium.
(Continued on next page)
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Background
Sepsis is defined as life-threatening organ dysfunction
caused by a dysregulated host response to infection [1].
A proportion of patients with sepsis develop
hypotension, due to such factors as vasodilation and
myocardial depression, that can lead to impaired tissue
perfusion [2]. The term ‘septic shock’ has been used to
describe a state of ‘acute circulatory failure’ in the
setting of infection [3]. In the recently updated Third
International Consensus Definitions for Sepsis and
Septic Shock (Sepsis-3), this term is reserved for the
subset of patients in which the underlying circulatory
and cellular metabolism abnormalities are such as to
substantially increase mortality [1]. Recognising the
importance of cellular and microcirculatory alterations
in sepsis pathogenesis, a threshold blood pressure is no
longer defined for septic shock. Notwithstanding these
changes in nomenclature, the conventional initial clinical
approach to the sepsis patient with evidence of
hypotension/hypoperfusion, as recommended by the
Surviving Sepsis Campaign (SSC) guidelines, remains
rapid intravenous (IV) infusion of 30 ml/kg of isotonic
crystalloid [4]. The rationale for this approach is to
restore circulating volume, and to increase stroke
volume by optimising cardiac preload. There is no
clinical trial data to support this, however, and advances
in our understanding of fluid physiology in critical
illness have challenged the underlying assumptions [5].
Challenges to conventional approach
Historically, ‘septic shock’ was understood in simple
terms to be synonymous with tissue hypoperfusion;
however, the syndrome proves to be far more complex
than this. Several lines of evidence challenge this over-
simplification. For example:
 Cardiac output may be preserved, increased or
depressed in patients with sepsis, although there is a
paucity of human studies undertaken in the ‘non-
resuscitated’ state [6]
 IV fluid loading has little, if any, effect on cardiac
output in critical illness [7], and any increase in
blood pressure is not sustained [8]
 Cellular hypoxia is not observed in experimental
models of sepsis or in clinical studies [9–11]
 Elevated serum lactate in sepsis is produced
aerobically, probably in response to adrenergic
stimulation, as an adaptive response to increase bio-
energetic efficiency, rather than because of tissue
hypoxia [12]
 Organ failure in sepsis involves cellular dysfunction
unrelated to hypoxia/hypoperfusion, including
structural mitochondrial changes and reduced
oxygen consumption [13]
 A key role is played by the microcirculation,
including the vascular endothelium, in the
pathogenesis of sepsis. These microcirculatory
alterations are not related to macrocirculatory
indices such as blood pressure [14]
It has been suggested that sepsis with hypotension and/
or elevated serum lactate is not strictly a ‘shock’ state, but
rather an adaptive alteration in haemodynamics and me-
tabolism [5]. For these reasons we have utilised the term
‘sepsis-associated hypotension’ rather than ‘septic shock’
to denote the clinical phenotype of interest in this trial.
Regardless of terminology, attempting to increase cardiac
output by administering a fixed, large volume of fluid
intravenously does not have a sound theoretical basis.
Is liberal intravenous fluid administration associated with
harm?
Accumulating observational evidence links the injudi-
cious use of intravenously administered fluids with
adverse outcome in sepsis, including requirement for
organ support and mortality [15–17]. The Fluid Expan-
sion As Supportive Therapy (FEAST) trial randomised
3400 children (median age 24 months) with sepsis and
evidence of hypoperfusion to receive bolus resuscitation
with either crystalloid saline or albumin, and a control
arm whose participants received only maintenance fluid
without bolus [18]. Despite early improvement in indices
of perfusion, the mortality rate at 48 h was 50% greater
in both fluid-bolus groups compared to no bolus (10.6%
versus 7.3%). Further analysis found that the excess
deaths were due to cardiovascular collapse rather than
to the respiratory or neurological complications of fluid
administration [19]. However, the trial was undertaken
in a resource-poor setting in sub-Saharan Africa. Conse-
quently, there was no access to invasive organ support,
over half the participants had malaria and one third were
severely anaemic. These factors prevent translation of
the results to adults in industrialised countries with
ready availability of intensive care. Nonetheless, the
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FEAST trial is currently the only randomised clinical
trial of fluid-bolus resuscitation in sepsis, and has
prompted a critical re-evaluation of this approach.
Why might intravenously administered fluid be harmful?
There are a number of plausible mechanisms by which
the inappropriate administration of fluids intravenously
may cause harm:
 Tissue oedema – leading to increased requirement
for ventilatory support, increased translocation of
gut organisms, and increased renal venous pressure
compromising perfusion [5]
 Opening of shut-down capillary beds (so called
‘hibernating circulation’) leading to ‘flooding’ of the
systemic circulation with cytokine-rich blood,
exacerbating systemic inflammation [5]
 Degradation of the glycocalyx layer lining the
luminal wall of the vascular endothelium [20]. The
glycocalyx plays a critical role in vascular
homeostasis by maintaining endothelial cells in a
quiescent state. Loss of integrity of the glycocalyx is
a critical step in endothelial cell activation and
propagation of the systemic inflammatory state.
Glycocalyceal damage occurs as a direct effect of
fluid administration intravenously [21]
Alternative approach
Vasopressor medications, such as noradrenaline, have
been used for decades to increase vascular tone and re-
verse the vasodilation and reduced afterload that charac-
terises the ‘classic’ distributive picture of septic shock.
Typically, a vasopressor infusion is utilised as a second-
line approach to reverse critical hypotension that
remains despite IV fluid loading of at least 30 ml/kg, as
per SSC guidelines [4]. The optimal timing of vasopres-
sor commencement remains a matter of clinical judge-
ment; like fluids, this specific question has not been the
subject of a randomised trial in sepsis. Concerns about
the potential harmful effects of vasopressor use in
patients who are ‘inadequately fluid-resuscitated’,
coupled with the operational requirements that such
drugs are administered via a central venous line, may
lead to reluctance to utilise vasopressors in a timely
fashion. Conversely, many patients with sepsis-
associated hypotension ‘respond’ to fluid administration
intravenously, at least initially, and the requirement to
start vasopressors and admit to a scarce critical care bed
may be avoided. These concerns are tempered by emer-
ging evidence of the safety of short-term peripheral
administration of vasopressors [22]. In addition, given in
low doses, noradrenaline exerts effects on venous
capacitance thereby increasing cardiac preload and
acting as a physiological ‘volume challenge’ without the
need for the administration of exogenous fluids [23].
Rationale for a randomised trial and the need for pilot
data
Excessive fluid administration leads to worse outcomes,
and the only clinical trial data demonstrates increased
mortality with fluid-bolus therapy [18]. However, for
generations physicians have been conditioned to pre-
scribe an IV fluid bolus as first-line treatment for shock.
Substantial reductions in sepsis mortality seen in the
past two decades have been associated with the intro-
duction of protocolised resuscitation for sepsis, includ-
ing liberal fluid administration. Waechter et al.
examined the effect of the volume of intravenously ad-
ministered fluid, and the timing of initiation of vasopres-
sors on mortality in a retrospective analysis of over 2000
intensive care unit (ICU) patients [24]. They found that
early, high-volume resuscitation in the first 6 h, moder-
ate fluid administration over the subsequent 6–24 h and
the timely initiation of vasopressors were associated with
the lowest mortality. However, it is unknown whether
reductions in mortality occurred as a result of, or in
spite of, intravenously administered fluids. Thus, at the
present time, there is equipoise regarding liberal or
conservative fluid-volume resuscitation in patients with
sepsis-associated hypotension [25, 26]. Given the
frequency of sepsis among patients admitted to ICU,
and the ubiquitous use of intravenously administered
fluids in these patients, there is a need for high-
quality clinical trial data to guide clinicians and opti-
mise patient outcomes. The REFRESH trial will,
therefore, compare a protocolised, restricted-volume
resuscitation approach (including the early use of
vasopressors, if required) with the standard-volume
approach recommended by the SSC.
While a large, multicentre clinical trial is required to
investigate the impact of this approach on clinically ori-
entated outcomes such as mortality, pilot data is essen-
tial to demonstrate the clinical acceptability of the
approach, adherence to the protocol, and whether clinic-
ally important differences in mean fluid volume can
actually be achieved [27]. The REFRESH trial also aims
to provide important mechanistic plausibility data via an
embedded biomarker study. Collectively, the results will
inform the design of a large trial with sufficient power to
detect differences in clinical outcomes.
Methods/design
Aim, design and setting
This is an investigator-initiated, multicentre, prospect-
ive, randomised open-label pilot (phase II) clinical
trial. It will be undertaken in the emergency depart-
ments (EDs) of a number of Australian hospitals.
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These include tertiary-referral and urban general hos-
pitals; at the time of submission six sites are open to
recruitment with a further two planned. A pragmatic
trial design will test the clinical feasibility of recruit-
ment and administration of the trial intervention,
along with an embedded laboratory study that will ex-
plore mechanistic plausibility. The protocol adheres to
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Statement (Table 1)
(see Additional file 1).
Participant characteristics
The trial will enrol 100 adult patients (aged 18 years or
older) with sepsis, according to the recently revised
standard consensus definition (Sepsis3) [1], presenting
to the ED of a participating hospital, and who have a
systolic blood pressure (SBP) < 100 mmHg, persisting
despite intravenous administration of a fluid bolus.
Inclusion criteria
1. Suspected infection and
2. Systolic blood pressure (SBP) < 100 mmHg*, despite
1000 ml isotonic crystalloid administered
intravenously over not more than 60 mins and
3. Study intervention can be administered within 2 h of
inclusion criteria being met
Exclusion criteria
1. Hypotension thought due to, or contributed to by, a
non-sepsis cause (e.g. arrhythmia, haemorrhage)
2. Clinical requirement for fluid replacement (e.g.
gastrointestinal losses)
3. Transfer from another hospital
4. More than 2000 ml* of intravenously administered
fluid has been given (pre-hospital, in ED, or both)
5. Likely requirement for immediate surgery
6. Age below 18 years
7. Pregnancy (confirmed or suspected)
8. Patient in extremis or death deemed imminent and
inevitable
9. Patient wishes or comorbidities such that either fluid
loading or vasopressor support is not considered
clinically appropriate
*The previous version of the protocol (V2, dated April
2016) required a systolic blood pressure < 90 mmHg for
inclusion, and excluded patients who had received >
1000 ml of fluid. These criteria were amended because
of a slow recruitment rate. A total of six participants
were enrolled under this protocol, all of which meet eli-
gibility for the trial in the current version.
Screening and randomisation
Patients with clinical features of infection will be
screened for sepsis using standard clinical procedures in-
cluding recording of vital signs, and collection of blood
samples including full blood count, urea and electrolytes
and a venous blood gas analysis including serum lactate.
Those who have a systolic blood pressure < 100 mmHg
on arrival, or who develop this during their ED stay, will
receive a 1000-ml IV fluid challenge with isotonic crys-
talloid over a maximum of 60 min. Patients whose blood
pressure remains < 100 mmHg, or whose blood pressure
falls below this threshold within 60 min of completing
the fluid challenge, and who do not have any exclusion
criteria will be invited to participate in the trial. Partici-
pants who fulfil the eligibility criteria and for whom con-
sent is obtained (see ‘Ethics and consent’ below) will be
randomised (1:1) to one of the study arms. The treating
clinician will perform randomisation in real time using a
dedicated, secure, password-protected web-based inter-
face. Allocation concealment will be maintained until
the conclusion of the online randomisation process.
Randomisation, using a computer-generated random
sequence, will be stratified by site in pre-allocated
blocks of 2 and 4, thus making it impossible to pre-
dict the last allocation in a block. For practical and
safety purposes randomised trial participants and the
treating team will not be blind to the trial interven-
tion. The staff conducting the laboratory analyses and
the trial statistician will be blinded to the treatment
allocation. The screening and enrolment procedure is
summarised in (see Additional file 2: Figure S1).
Study interventions
General management – all participants
1. Supplemental oxygen to maintain SpO2 > 92%
2. Antibiotics within 60 min of enrolment
3. Ventilation (non-invasive) or intubation and
mechanical ventilation, if clinically indicated, using a
lung preventive strategy as recommended by SSC
guidelines [4]; consider ketamine for induction to
minimise risk of hypotension
4. All fluids administered (bolus or maintenance)
subsequent to enrolment to be balanced isotonic
crystalloid during the first 6 h. Hypotonic fluids and
synthetic colloids and 0.9% saline are to be avoided.
Blood products and albumin may be given at
treating clinician discretion. Actual (unadjusted)
volumes of all non-crystalloid fluids will be recorded
5. Fluid management will be as per study protocol
for the first 6 h post randomisation regardless of
whether the patient remains in the ED or is
transferred to ICU or to a ward. For patients
with an unanticipated transfer to theatre for
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Table 1 REstricted Fluid REsuscitation in Sepsis-associated Hypotension (REFRESH) trial Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) protocol summary
Scientific title Fluid-restricted versus fluid-liberal resuscitation in sepsis; a randomised controlled pilot trial
Short title REstricted Fluid REsucitation in Sepsis-associated Hypotension (REFRESH) trial
Health condition Sepsis
Ethics HREC/15/Austin/486 (Austin Health, Victoria) & HREC/15/114 (South Metropolitan Health Service, WA)
Protocol version Version 3, October 2016
Funding Grants:
Emergency Medicine Foundation (EMSS-229R24-2015-KEIJZERS)
University of WA/University of Queensland Bilateral Research Collaboration Award
Royal Perth Hospital Medical Research Foundation
Industry:
Nil
Primary sponsor Investigator-initiated and -driven study. Centre for Clinical Research in Emergency Medicine, University of
Western Australia. Chief investigator and study contact: Dr. Stephen Macdonald, Royal Perth Hospital, PO
Box X2213, Perth, WA, Australia
Email: stephen.macdonald@uwa.edu.au
Background Sepsis is a common condition with high morbidity and mortality. Patients with sepsis can develop
hypotension (low blood pressure) due to a combination of factors. The traditional first-line treatment
of sepsis-associated hypotension is to give a rapid, large volume of intravenously administered fluid
(fluid bolus). Emerging clinical data and advances in the understanding of fluid physiology suggest
that fluid bolus may be associated with worse patient outcomes. This randomised pilot clinical trial
will compare a restricted fluid-volume approach, including early use of vasopressor drugs if required,
against standard (liberal fluid-volume) care to assess the feasibility and safety of this approach. An
embedded laboratory study will measure the differences in a range of relevant blood markers (such as
activation of the vascular endothelium) to provide mechanistic plausibility for a restricted-volume approach.
Together these data will be used to inform the design of a large multicentre trial to assess clinical outcomes
Hypothesis That a volume-restricted approach to sepsis-associated hypotension is clinically feasible; that this
approach results in reduced systemic inflammation and associated biomarkers of endothelial cell activation
Study aims 1. To investigate the feasibility of delivering volume-restricted resuscitation in sepsis-associated hypotension
2. Compare the total volume of fluid administered at 6 h and 24 h
3. To assess effects on the biomarkers of the inflammatory response, endothelial activation and related
pathways of interest
4. To record any differences in requirement for organ support and in clinical outcomes
Study design • Multi-centre (Armadale, Perth/Austin, Melbourne/Fiona Stanley, Perth/Gold Coast/Royal Hobart/Royal
Perth/Sir Charles Gairdner, Perth/The Prince Charles, Brisbane)
• Randomised controlled/un-blinded/feasibility
• Interventional
Setting 8 emergency departments (EDs) in Australia
Inclusion and exclusion criteria Inclusion criteria:
1. Suspected infection and
2. Systolic blood pressure (SBP) < 100 mmHg, despite 1000 ml intravenously administered isotonic
crystalloid administered over not more than 60 minutes and
3. Study intervention can be administered within 2 hs of inclusion criteria being met
Exclusion criteria:
1. Hypotension thought due to, or contributed to by, a non-sepsis cause (e.g. arrhythmia, haemorrhage)
2. Clinical requirement for fluid replacement (e.g. gastrointestinal losses)
3. Transfer from another hospital
4. More than 2000 ml intravenously administered fluid has been given (pre-hospital, in ED, or both)
5. Likely requirement for immediate surgery
6. Age < 18 years
7. Pregnancy (confirmed or suspected)
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Table 1 REstricted Fluid REsuscitation in Sepsis-associated Hypotension (REFRESH) trial Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) protocol summary (Continued)
8. Patient in extremis or death deemed imminent and inevitable
9. Patient wishes or comorbidities such that either fluid loading or vasopressor support is not
considered clinically appropriate
Intervention Intervention arm:
Commence vasopressor infusion (± maintenance IV fluid) if SBP < 90 mmHg or mean arterial pressure (MAP)
< 65 mmHg). Reassess hourly next 6 h and administer further 250-ml IV fluid bolus if required
Comparator arm:
Give a second 1000-ml fluid bolus plus further 500-ml boluses as clinically indicated until judged to be
euvolaemic. Commence vasopressor infusion (± maintenance IV fluid) if SBP < 90 mmHg or
MAP < 65 mmHg). Reassess hourly next 6 h and administer further 500-ml IV fluid bolus if required
Primary outcome measure Total volume of intravenously administered fluid (including pre-randomisation) at 6 h
Secondary outcome measures • Mortality (all-cause) at 90 days post enrolment
• ICU length of stay
• Hospital length of stay
• Hospital-free days to day 90
• Organ failure
o Cardiovascular
▪ Requirement for vasopressors
▪ Duration of vasopressor requirement (h)
▪ Vasopressor-free days to day 28
o Respiratory
▪ Requirement for ventilation (NIV/IPPV)
▪ Duration of ventilator support (h)
▪ Ventilator-free days to day 28
o Renal
▪ Requirement for renal replacement therapy (RRT)
▪ Duration of RRT
▪ RRT-free days to day 28
▪ AKIN score to day 7
Laboratory/mechanistic outcome measures Peak values, as well as patterns of expression over time (T0–T24), will be analysed for a range of biomarkers
and compared between the groups including:
• Atrial natriuretic peptide
• Troponin
• Inflammatory cytokines
o IL-6, IL-10, resistin
• NGAL (a biomarker of renal injury)
• Endothelial cell activation biomarkers
o sVCAM, sICAM, sE-Selectin, sFlt-1
• Soluble markers of glycocalyx degradation
o Heparan sulphate, syndecan-1, hyaluronan
Feasibility outcome measures • Proportion of eligible patients enrolled
• Randomisation errors
• Compliance – protocol violations
• Proportion with completely recorded data
• Proportion with complete study blood sampling
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Table 1 REstricted Fluid REsuscitation in Sepsis-associated Hypotension (REFRESH) trial Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) protocol summary (Continued)
Sample size 50 per arm/100 total
Randomisation Eligible participants in whom a consent process has been commenced will be randomised to either the
fluid-volume restricted or the fluid-liberal (standard-care arm)
Randomisation procedure • Eligibility assessment and randomisation conducted by clinical staff with support by research personnel
(in person or by telephone)
• Computer-generated randomisation sequence
• Real-time web-based randomisation
• 1:1 randomisation in blocks of 2 or 4
Blinding • Un-blinded to patients and to treating team
• Blinding of laboratory staff and data analysts
Data collection methods • Paper CRF completed for each participant
• CRF populated by research staff in real time or from clinical record
• Subsequent data entry into secure database by trained research assistant
• Audit of data entry against source documentation
Data collected • All fluids administered pre-randomisation
• All fluids administered post randomisation – 6 h (recorded hourly)
• All fluids administered over 6–24 h
• Urine output to 24 h
• Vital signs at enrolment and hourly until 6 h
• Antimicrobials – agent, dose and time administered
• Corticosteroid administration
• Source of sepsis (suspected/proven)
• Charlson Comorbidity Score
• Microbiological/serological results from samples obtained in first 24 h
• Sequential Organ Failure Assessment (SOFA) score at admission and at 24 h
• Acute Physiology and Chronic Health Evaluation (APACHE) II score (peak first 24 h)
• Acute Kidney INjury (AKIN) score up to 7 days
• Study blood sampling at enrolment (T0), 3 h (T3), 6 h (T6) and 12–24 h (T24)
Statistical analysis • Intention-to-treat analysis
• Statistician blinded to treatment allocation
Data and safety monitoring • DSMC – emergency physician, intensive care physician, statistician
• SAE reporting to study coordination centre within 24 h
• DSMC review all SAE
• Periodic data review by DSMC and recommendations to PI in event of study conduct of SAE issues
• Trial coordinator will monitor trial conduct at each site at regular intervals
Ethics and governance • HREC approvals obtained for all sites
• Clinical governance (site-specific authority) procedures in place for all sites
• Any subsequent protocol amendments to be submitted to lead ethics site with appropriate
dissemination to participating study sites
• The study will be conducted in accordance with GCP
Consent • Where possible, prospective informed consent will be obtained
• Due to the time-critical nature of the condition, approval in place for verbal consent to randomise and
initiate care followed by formal written consent process
• Some participants will lack capacity so consent will be sought from next of kin
• Where next of kin not immediately available, provision in place for enrolment under initial waiver of
consent (or procedural authorisation) followed by delayed consent to continue in the trial
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surgery during this time the trial protocol will be
suspended
Restricted-volume (±early vasopressor) arm (see Additional
file 3: Figure S2)
Management following randomisation after the initial
1000-ml fluid bolus for the next 6 h:
1. Continue fluid infusion intravenously at a
maintenance rate of 1–2 ml/kg/h (max 150 ml/h)
via infusion pump, as clinically indicated
2. If SBP < 90 mmHg or mean arterial pressure (MAP)
< 65 mmHg:
(a)Start noradrenaline* infusion by peripheral IV
route (large vein) and titrate to maintain MAP at
65–70 mmHg
(b)Insertion of urinary catheter and hourly urine
output measures
(c)Insertion of central venous access (central venous
catheter (CVC)/ peripheral intravenous central
catheter (PICC)) and commencement of central
noradrenaline infusion once correct position
confirmed by chest X-ray. Alternatively, at phys-
ician discretion and according to local protocol, if
the anticipated duration of vasopressor require-
ment is less than 6 h the infusion can continue
via a dedicated secure peripheral large venous
cannula if the patient is monitored in a critical
care environment and there is no other indication
for central access
(d)Arterial line at the discretion of the treating
clinician
(e)Titration and weaning of vasopressors as per
treating clinician and local protocols
(f ) Additional therapies, e.g. vasopressin,
corticosteroids at the treating clinician’s
discretion
(g)If, in the judgement of the treating clinician
(based upon clinical assessment, central venous
pressure (CVP), ultrasound, etc.), the patient
remains hypovolaemic, a further 1000-ml isotonic
crystalloid bolus is permitted
3. Reassess each hour for the first 6 h. At each
reassessment consider need for further fluid bolus
based upon clinical assessment, including:
(a)Mental status, skin perfusion
(b)Urine output
(c)Repeat lactate (if initially elevated)
(d)Ultrasound/echocardiography or CVP if available
If the treating clinician judges additional fluid to be
required, administer an additional 250-ml isotonic
crystalloid IV bolus.
Standard treatment arm (see Additional file 4: Figure S3)
Management following randomisation after the initial
1000-ml fluid bolus for the next 6 h:
1. Give a second fluid bolus of 1000 ml (balanced
isotonic crystalloid)
2. Reassess
(a) If SBP ≥ 90 mmHg and MAP ≥ 65 mmHg give
maintenance rate of 1–2 ml/kg/h (max 150 ml/h)
via infusion pump, as clinically indicated
(b)If SBP < 90 mmHg or MAP < 65 mmHg:
i. Give further 500-ml boluses, at least every 30
min, until the treating clinician judges
euvolaemia to be achieved
ii. Once euvolaemia is deemed present (e.g.
inferior vena cava (IVC) non-collapsing on
ultrasound, CVP > 8 mmHg, distended neck
veins, etc.) and if the patient remains
hypotensive:
1. Start noradrenaline* infusion by peripheral
IV route (large vein) and titrate to maintain
MAP at 65–70 mmHg
2. Insertion of urinary catheter and hourly
urine output measures
Table 1 REstricted Fluid REsuscitation in Sepsis-associated Hypotension (REFRESH) trial Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) protocol summary (Continued)
Confidentiality • All data will be de-identified
• Data (paper and electronic) will be stored securely
Dissemination • Trial results to be presented at relevant scientific meetings and published in peer-reviewed journal
Study status • Opened to recruitment July 2016 (Protocol V2)
• Protocol amended October 2016 (Protocol V3) after 6 participants enrolled
• As at 22 June 2017, 42 participants enrolled at 6 of 7 sites active
• Anticipated to complete enrolment of 100 participants within 12 months
AKIN Acute Kidney Injury Network, CRF Case Report Form, DSMC Data Safety Monitoring Committee, GCP Good Clinical Practice, ICAM intercellular adhesion
molecule, IL interleukin, IPPV intermittent positive-pressure ventilation; IV intravenous, NGA neutrophil gelatinase-associated lipocalin, NIV non-invasive ventilation,
PI principal investigator, SAE serious adverse event, VCAM vascular cell adhesion molecule
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3. Insertion of a central venous access (CVC/
PICC) and commencement of central
noradrenaline infusion once correct position
confirmed by chest X-ray. Alternatively, at
physician discretion and according to local
protocol, if the anticipated duration of vaso-
pressor requirement is less than 6 h the in-
fusion can continue via a dedicated secure
peripheral large venous cannula if the pa-
tient is monitored in a critical care environ-
ment and there is no other indication for
central access
4. Arterial line at the discretion of the treating
clinician
5. Titration and weaning of vasopressors as
per treating clinician and local protocols
6. Additional therapies, e.g. vasopressin,
corticosteroids at the treating clinician’s
discretion
3. Reassess each hour for the first 6 h. At each
reassessment consider the need for further fluid
boluses based upon clinical assessment, including:
(a)Mental status, skin perfusion
(b)Urine output
(c)Repeat lactate (if initially elevated)
(d)Ultrasound/echocardiography or CVP if available
If the treating clinician judges additional fluid to be
required, administer an additional 500-ml isotonic
crystalloid IV bolus.
*An infusion of metaraminol via a peripheral IV
cannula may be considered as an alternative to
noradrenaline in accordance with local hospital policy.
Study measurements
Clinical
 All fluids administered pre-randomisation
 All fluids administered post-randomisation – 6 h
(recorded hourly)
 All fluids administered over 6–24 h
 Urine output to 24 h
 Vital signs at enrolment and hourly until 6 h
 Antimicrobials – agent, dose and time administered
 Corticosteroid administration
 Source of sepsis (suspected/proven)
 Charlson Comorbidity Score [28]
 Microbiological/serological results from samples
obtained in first 24 h
 Sequential Organ Failure Assessment (SOFA) score
[29] at admission and at 24 h
 Acute Physiology and Chronic Health Evaluation
(APACHE) II score [30] (peak first 24 h)
Laboratory Study blood sampling:
 Enrolment (T0), 3 h (T3), 6 h (T6) and 12–24 h (T24)
 Plasma and serum samples (total 5 ml) at each
sampling time point
 Blood gas (arterial or venous) including lactate and
haemoglobin at each sampling time point
 Blood samples should not to be taken during fluid-
bolus administration and should be taken from the
opposite arm from any maintenance fluid being
administered
Samples will be centrifuged and the extracted sera/
plasma divided into 500-μl aliquots and stored at −80 °C
for subsequent batch analysis.
Strategies to ensure protocol compliance and data integrity
Digital copies of de-identified Case Report Forms will be
submitted electronically to the trial coordination centre
at the following time points; enrolment, completion of
hospital stay, 28 days and 90 days. This will allow for
checking and data queries to be undertaken in a timely
manner. This will also identify any protocol deviations
and provide opportunity for feedback to the site investi-
gator. A trained research assistant at the trial coordin-
ation centre will upload data into a secure trial database.
There will be periodic internal audits of data accuracy
and compliance.
Outcome measures
Consistent with the exploratory pilot nature of this
study, multiple feasibility, process-of-care, clinical and
mechanistic outcomes will be evaluated. The primary
outcome relates to achieving a difference in the volume
of intravenously administered fluid to the groups. All
analyses will be by intention-to-treat.
Primary outcome
 A clinically and statistically significant difference
in mean total fluid volume administered at 6 h
post randomisation (including pre-randomisation).
In addition pre- and post-randomisation volumes
will be reported separately. See ‘Statistical
methods and sample size calculation’ below.
Secondary outcomes: feasibility
 Proportion of screened patients eligible
 Proportion of eligible patients enrolled
 Enrolment rate (i.e. number of enrolments per
month per site)
 Protocol compliance
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Secondary outcomes: process-of-care
 Admission rate to ICU versus general ward
 Rates and timing of CVC insertion
 Peripheral versus central administration of
vasopressors
Secondary outcomes: clinical
 Mortality (all-cause) at 90 days post enrolment
 ICU length of stay
 Hospital length of stay (acute)
 Hospital-free days to day 90 (acute)
 Organ failure
o Cardiovascular
▪ Administration of vasopressors
▪ Duration of vasopressor requirement (h)
▪ Vasopressor-free days to day 28
o Respiratory
▪ Requirement for ventilation (non-invasive ventilation
(NIV)/intermittent positive-pressure ventilation (IPPV))
▪ Duration of ventilator support (h)
▪ Ventilator-free days to day 28
o Renal
▪ Requirement for renal replacement therapy (RRT)
▪ Duration of RRT
▪ RRT-free days to day 28
▪ Acute Kidney Injury Network (AKIN) score to day
7 [31]
Laboratory/mechanistic outcomes
Peak values, as well as patterns of expression over time
(T0–T24), will be analysed for a range of biomarkers
and compared between the groups including:
 Atrial natriuretic peptide
 Troponin
 Inflammatory cytokines
o Interleukin (IL)-6, IL-10, resistin
 Neutrophil gelatinase-associated lipocalin (NGAL; a
biomarker of renal injury)
 Endothelial cell activation biomarkers
o sVCAM, sICAM, sE-Selectin, sFlt-1
 Soluble markers of glycocalyx degradation
o Heparan sulphate, syndecan-1, hyaluronan
All laboratory analyses will be performed and the re-
sults collated by laboratory staff blinded to the study
group allocation. As a pragmatic, open-label trial, treat-
ing clinicians and participants will be aware of the treat-
ment allocation.
The schedule of enrolment, interventions and assess-
ments is shown in Fig. 1.
Statistical methods and sample size calculation
The primary outcome is the achievement of a minimum
clinically significant relative difference of 33% in the
total cumulative fluid volume administered until T6 (in-
cluding pre-randomisation fluids). In the control arm of
an Australasian, multicentre randomised controlled trial
STUDY PERIOD
Enrolment Allocation Post-allocation (hourly time points) Follow up
















Organ failure free 
days
X
Hospital free days X
Mortality X
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure
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of early goal-directed therapy in septic shock, the mean
total volume administered within the first 6 h was 4200
± 2650 ml [32]. We aim to achieve a reduction of 33%,
to a mean of 2800 ± 1800 ml over 6 h in the restricted-
volume arm compared to the standard-care arm. This
will require 43 participants in each group to achieve 80%
power with α = 0.05. This pilot trial is not designed to
have sufficient power to detect differences in secondary
clinical outcomes.
The trial will also measure a range of biochemical
markers. There is limited relevant data to inform sample
size calculations for these analyses. Based upon feasible
recruitment within a 12-month time period, a sample
size of 100 is attainable. This will allow a margin of
safety for achieving differences in the primary outcome.
It will also enable the detection of differences between
means of the two treatment groups of 55.6% of the
standard deviation (or larger) for the measured bio-
marker, with 80% power and α = 0.05. This calculation is
based upon a cross-sectional t test, not a repeated mea-
sures test (which affords additional power). As such,
these calculations are conservative.
Baseline clinical and demographic data will be analysed
using chi-square or Fisher’s exact test for categorical data,
and the Wilcoxon rank-sum test for continuous data.
Where biomarkers are normally or log-normally dis-
tributed, linear mixed models with maximum likelihood
estimation will be employed to analyse the pattern over
time. Differences in the pattern of expression of each
biomarker between the groups will be tested by the
interaction of time and group in the model. Additional
covariates will be added to adjust for treating centre,
illness severity and comorbidities. For biomarkers with
skewed distributions resistant to successful transform-
ation, quantile regression with per-person cluster adjust-
ment will be used.
A biostatistician will perform the statistical analysis.
Trial administration and Data Safety Monitoring
Committee
Trial coordination will be by the Centre for Clinical Re-
search in Emergency Medicine (CCREM) at the Univer-
sity of Western Australia, Perth, Australia. Case Report
Forms will be completed by site investigators and sent
electronically (after removal of individual patient identi-
fiers) to the trial coordination centre for checking and
data entry into a purpose-designed secure Research Elec-
tronic Data Capture (REDCap – Vanderbilt University,
Nashville, TN, USA) database hosted by the University
of Western Australia. Study blood samples will be proc-
essed at local hospital laboratories and stored for subse-
quent bulk shipping to the coordinating centre. All
biomarker analyses will be performed in house at the
CCREM laboratory facility in Perth.
The trial will be overseen by a Steering Committee,
comprising site investigators from each participating site.
The Steering Committee will meet monthly by teleconfer-
ence. An independent Data Safety Monitoring Committee
(DSMC) comprising an emergency physician, intensive
care physician and biostatistician has been appointed to
oversee the trial and will undertake periodic reviews at the
discretion of the chair. The DSMC will review all deaths
and adverse events (see below) and have the authority to
suspend or halt recruitment if necessary. The DMSC will
also assess relevant emerging published academic litera-
ture favouring one of the arms of the trial. Due to the
small numbers precluding determination of any statisti-
cally significant difference in clinical outcomes between
the arms, no formal interim analysis will be undertaken
and no stopping rules are specified.
Adverse events
Adverse events (AEs) are defined as any untoward medical
occurrence in a patient administered an investigational
intervention which does not necessarily require to have a
causal relationship with this intervention.
Patients with severe sepsis in the ED and ICU com-
monly have aberrations in laboratory values, signs and
symptoms due to the severity of their underlying disease
and the impact of standard therapies [33]. These will not
necessarily constitute an AE unless they require significant
amelioration or are considered to be of concern in the in-
vestigator’s clinical judgment. AEs include all unexpected
and/or untoward medical events experienced by the
patient which are not part of the expected course of sepsis.
The following will be considered AEs, regardless of
study treatment allocation and subsequent intervention
required:
 Extravasation of peripherally administered








 Arterial catheter-related complications, including
thrombosis
 Any other event that is considered to be of
concern by the site investigator
The AEs listed above will be recorded from the time
of commencement of study treatment to 72 h post inter-
vention. CVC-related complications, including infection,
will be considered an AE for as long as the CVC remains
in situ.
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All AEs will be reported, irrespective of treatment allo-
cation to the chief investigator and/or the REFRESH
Management Committee and then forwarded to the
chair of the DSMC.
Serious adverse events
A serious adverse event (SAE) is defined as any unto-
ward medical occurrence that:
 Results in death
 Is life-threatening
 Requires inpatient hospitalisation or prolongation of
existing hospitalisation
 Results in persistent or significant disability/incapacity
 Is an important medical event, which may require
intervention to prevent one of the previously listed
outcomes
In this study, all SAEs will be reported regardless of
suspected causality.
Adverse event and serious adverse event reporting
Separate Case Report Forms will be developed to record
AEs and SAEs. SAEs occurring from the time of com-
mencement of study treatment to 72 h post intervention
will be reported to the coordinating centre by faxing the
supplied SAE Form within 24 h of site study staff be-
coming aware of the event. In this pilot trial, all deaths
up to day 30 will be reported as a SAE. Coordinating
centre staff will be responsible for following up SAEs to
ensure that all details are available. It is the responsibility
of each site to inform their Human Research Ethics
Committee (HREC) of all SAEs which occur at their site,
in accordance with local requirements.
All SAEs will be forwarded to the chair of the DSMC
within 24 h of receipt at the REFRESH coordinating
centre. As detailed in the Patient Information and Con-
sent Form, any injury or complication occurring as a re-
sult of trial participation is to be reported to the study
team who will arrange all necessary medical treatment.
In Australia, Medicare will provide any required medical
treatment, free of charge, in a public hospital.
Strategies to achieve adequate enrolment
An education package has been developed for staff at
enrolling sites. In addition, individual site visits (physical
or virtual) will be undertaken at trial commencement.
The Trial Steering Committee will meet by teleconfer-
ence at least monthly and review enrolment rates and
discuss strategies to maximise these. Several sites have
dedicated research nurses in the ED who will actively
screen for eligibility. Finally, the trial will be publicised
by presentations at academic meetings and via social
media platforms – e.g. Twitter @REFRESH_Trial.
Discussion
Significance
This will be the first randomised trial examining the
question of fluid volume in the early resuscitation of
adult patients with sepsis-associated hypotension in a
mature health care system with access to advanced crit-
ical care. This is an important clinical question given the
findings of observational studies and the FEAST trial
[18]. Given the universal use of fluids to manage this
condition, superiority of a restricted approach is likely to
have significant clinical and economic impact. A recent
trial demonstrated the feasibility of a restricted-volume
approach to sepsis in ICU [34]. However, the median
volume of fluid administered prior to randomisation was
over 4 l. By recruiting patients in the ED, at the earliest
point in the course of their care, we aim to investigate
very early resuscitation. This essentially replicates the
approach of the FEAST trial [18], but in an industria-
lised country with access to advanced critical care.
Undertaking such a trial in the ED setting presents
considerable challenges. Unlike the ICU, patients present
to the ED with undifferentiated illness. Sepsis is a highly
heterogeneous condition. Often the onset of illness is
insidious, and the clinical presentations highly variable.
In addition, sepsis is a clinical syndrome and there is a
lack of a standard diagnostic test. Nevertheless, the
ARISE trial [32] demonstrated that the identification and
enrolment of patients with sepsis into a clinical trial in
Australian EDs is possible.
The REFRESH trial will provide essential feasibility
and mechanistic plausibility data to support a large-
scale clinical trial. A multicentre pilot will allow
assessment of the feasibility of delivering the protocol
in a range of settings. For example, participating sites
are inclusive of both tertiary referral centres and
urban general hospitals. A number of sites have substan-
tial research infrastructure, including research nurses
within the ED, whereas at other sites the trial will rely on
enrolments by clinical staff. Metrics, such as rates of
recruitment of eligible patients and adherence to the trial
protocol, will be assessed as part of the feasibility objec-
tives. All this information will be utilised in designing the
optimal protocol for a trial that is clinically acceptable and
operationally achievable.
Limitations
An open-label design confers challenges but is unavoid-
able given the nature of the trial intervention. Potential
bias arises due to the treating clinician being aware of
the treatment allocation. The pragmatic nature of the
trial allows for some latitude for the clinician to deter-
mine fluid volumes within set parameters; however, it is
difficult to control for individual behaviours and treating
physician preference for one approach over another. An
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additional potential challenge may be the reluctance to
give fluid in the standard-care arm on the basis of per-
ceived potential harms (the rationale for the trial). To
counter this, regular feedback and educational sessions
with clinicians will occur throughout the trial. For this
pilot trial, the primary feasibility outcomes are objective
measures (e.g. fluid volumes, processes of care). Clinical
outcome measures are also objective and pre-specified,
e.g. mortality, organ failure. However to minimise any
potential risk of bias, a physician-investigator will adju-
dicate clinical outcomes blinded to group allocation.
Similarly, laboratory analyses will be conducted in
blinded fashion.
Stakeholder engagement and dissemination of findings
The investigator team comprise clinicians in emer-
gency medicine and intensive care who have substan-
tial experience in conducting research among
critically ill patients. The REFRESH protocol has been
developed over an 18-month period during which
extensive consultations took place. The protocol has
been informed by practical feedback including from
clinician groups locally at participating sites, and
following presentation at the Australian and New
Zealand Intensive Care Society Clinical Trials Group
(CTG), and the Annual Scientific Meeting of the
Australasian College for Emergency Medicine
(ACEM). The REFRESH trial has received formal
endorsement from the ACEM CTG.
The trial results will be of wide interest to the global
emergency and critical care communities. It is antici-
pated that the results will be used to inform the design
of, and secure funding for, a large-scale clinical trial to
evaluate patient-centred outcomes. The results of the
trial will be submitted for publication in a suitable inter-
national journal. A writing committee will be convened
from among the Trial Steering Committee. Authorship
criteria will be according to the International Committee
of Medical Journal Editor definition.
Trial status
At the time of submission the REFRESH trial has
enrolled 42 of its planned 100 participants.
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includes emergency and intensive care settings, such as applies in the
present study, where research is necessary to improve the safety and
efficiency of interventions used in their treatment.
Participants in this trial will have low blood pressure in the setting of sepsis
and there is a short time window in which this must be treated by the
administration of one of the two trial interventions. Several approaches will
be adopted. When a conscious and comprehending patient is eligible, a
brief verbal explanation of the study (following a standard script) will be
given and a provisional verbal consent obtained to allow randomisation and
initiation of timely intervention. This script is attached as an Appendix (see
Additional file 5). This will be followed by provision of a written Participant
Information Sheet. If the patient chooses not to continue they will be
withdrawn from the trial and their care will revert to standard management
according to the treating physician. This will be recorded in the trial
screening logs. Where a patient’s condition precludes giving prospective
informed consent, they may be enrolled under an initial waiver of consent
(or procedural authorisation in Victoria). Following this, formal consent will
be obtained from the ‘person responsible’ for the patient, generally a close
family member. This may be in person, or by telephone. If telephone
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followed up by a formal written consent, as soon as practicable.
When the participant regains capacity, consent will be sought to
continue in the study. Participants may choose to withdraw from the
study (or be withdrawn by the ‘person responsible’ if enrolled under
waiver of consent) at any stage. Under these circumstances, permission
will be sought to use data and samples collected to that time point.
This withdrawal will be recorded in the study logs and care will revert
to standard management according to the treating team. The consent
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